Tag:
hepatitis B
Latest Headlines
Latest Headlines
Diabetics under 60 should get hep B vaccine
In addition to its recommendations about the HPV shot for boys, the CDC's Advisory Committee on Immunization Practices said diabetics under the age of 60 should get the hepatitis B vaccine. Experts
Inovio, VGX ink hep B and C vaccine deal
Blue Bell, PA-based Inovio Pharmaceuticals and VGX International will collaborate on the development of Inovio's synthetic vaccines for hepatitis B and hepatitis C. Financial details of the deal were
HepB vax Heplisav posts positive Ph3 data
Dynavax ($DVAX), which is based in Berkeley, CA, released a new round of Phase III data on its hepatitis B vaccine, Heplisav. The data focused on specific hypo-responsive groups--males, smokers and
Dynavax's Heplisav performs well, but shows product inconsistency
Despite generally positive late-stage results for its experimental hepatitis B vaccine, Heplisav, Dynavax's stock price suffered after test lots showed product inconsistencies and a loss in Q2
The CIA, bin Laden and the future of vaccine programs
As U.S. intelligence zeroed in on Osama bin Laden's location in Abbottabad, Pakistan, the CIA found a useful front to obtain his family DNA: a hepatitis B vaccine program. It's unknown if the CIA
Merck, Sanofi start Ph3 pediatric vax trial
Investigators have started a Phase III study in the U.S. of a hexavalent pediatric vaccine created by Merck and Sanofi Pasteur. The vaccine is designed to protect against diphtheria, tetanus,
Vaccines may prevent certain childhood cancers
A study published in the Journal of Pediatrics finds that some vaccines may lower the risk of certain childhood cancers, including leukemia. Specifically, children who received the hepatitis B shot
Gates: Disease prevention most beneficial in developing countries
In a move to continue supporting vaccination efforts abroad, Bill Gates donated $50 million to fund a myriad of vaccinations in the Middle East. And this time, he had matched support from Sheik
Pharmasset touts promising PhIIa hep C data
Pharmasset (NASDAQ: VRUS) touted a promising batch of mid-stage data for its hepatitis C therapy and promised to swiftly pivot into a Phase IIb trial that could provide longer-term feedback on
Vaccination campaigns beat back viral hepatitis
The most serious types of viral hepatitis show signs of a steady retreat, beaten back by years of persistent vaccination campaigns in the U.S. Experts at the CDC say that there's been a decrease of
